Long-term melatonin treatment reduces ovarian mass and enhances tissue antioxidant defenses during ovulation in the rat

Melatonin regulates the reproductive cycle, energy metabolism and may also act as a potential antioxidant indoleamine. The present study was undertaken to investigate whether long-term melatonin treatment can induce reproductive alterations and if it can protect ovarian tissue against lipid peroxidation during ovulation. Twenty-four adult female Wistar rats, 60 days old (± 250-260 g), were randomly divided into two equal groups. The control group received 0.3 mL 0.9% NaCl + 0.04 mL 95% ethanol as vehicle, and the melatonin-treated group received vehicle + melatonin (100 µg·100 g body weight-1·day-1) both intraperitoneally daily for 60 days. All animals were killed by decapitation during the morning estrus at 4:00 am. Body weight gain and body mass index were reduced by melatonin after 10 days of treatment (P < 0.05). Also, a marked loss of appetite was observed with a fall in food intake, energy intake (melatonin 51.41 ± 1.28 vs control 57.35 ± 1.34 kcal/day) and glucose levels (melatonin 80.3 ± 4.49 vs control 103.5 ± 5.47 mg/dL) towards the end of treatment. Melatonin itself and changes in energy balance promoted reductions in ovarian mass (20.2%) and estrous cycle remained extensive (26.7%), arresting at diestrus. Regarding the oxidative profile, lipid hydroperoxide levels decreased after melatonin treatment (6.9%) and total antioxidant substances were enhanced within the ovaries (23.9%). Additionally, melatonin increased superoxide dismutase (21.3%), catalase (23.6%) and glutathione-reductase (14.8%) activities and the reducing power (10.2% GSH/GSSG ratio). We suggest that melatonin alters ovarian mass and estrous cyclicity and protects the ovaries by increasing superoxide dismutase, catalase and glutathione-reductase activities.21722

Effects Of P-mapa Immunomodulator On Toll-like Receptors And P53:potential Therapeutic Strategies For Infectious Diseases And Cancer

Background: Compounds that can act as agonists for toll-like receptors (TLRs) may be promising candidates for the development of drugs against infectious diseases and cancer. The present study aimed to characterize the immunomodulatory effects of P-MAPA on TLRs in vitro and in vivo, as well as to investigate its potential as adjuvant therapy in infectious diseases and cancer. Methods: For these purposes, the activity of P-MAPA on TLRs was assayed in vitro through NF-κB activation in HEK293 cells expressing a given TLR, and using an in vivo animal model for bladder cancer (BC). The antimicrobial activity of P-MAPA was tested against Mycobacterium tuberculosis (TB) in vitro in an MIC assay, and in vivo using an aerosol infection model of murine tuberculosis. Antitumor effects of P-MAPA were tested in an animal model with experimentally induced BC. Moxifloxacin (MXF) and Bacillus Calmette-Guerin (BCG) were used as positive controls in the animal models. Results: The results showed that P-MAPA, administered alone or in combination with MXF, induced significant responses in vivo against TB. In contrast, the compound did not show antimicrobial activity in vitro. P-MAPA showed a significant stimulatory effect on human TLR2 and TLR4 in vitro. In BC, TLR2, TLR4 and p53 protein levels were significantly higher in the P-MAPA group than in the BCG group. The most common histopathological changes in each group were papillary carcinoma in BC group, low-grade intraepithelial neoplasia in BCG group and simple hyperplasia in P-MAPA group. Concerning the toxicological analysis performed during BC treatment, P-MAPA did not show evidence for hepatotoxicity and nephrotoxicity. Conclusions: In conclusion, P-MAPA acted as TLR ligand in vitro and improved the immunological status in BC, increasing TLR2 and TLR4 protein levels. P-MAPA immunotherapy was more effective in restoring p53 and TLRs reactivities and showed significantly greater antitumor activity than BCG. The activation of TLRs and p53 may provide a hypothetical mechanism for the therapeutic effects in both cancer and infectious diseases. Taken together data obtained will encourage the further investigation of P-MAPA as a potential candidate for the treatment of cancer and infectious diseases. © 2012 Fávaro et al.; licensee BioMed Central Ltd.71Waldmann, T.A., Immunotherapy: Past, present and future (2003) Nature Medicine, 9 (3), pp. 269-277. , DOI 10.1038/nm0303-269Steinman, R.M., Mellman, I., Immunotherapy: Bewitched, bothered, and bewildered no more (2004) Science, 305 (5681), pp. 197-200. , DOI 10.1126/science.1099688Curiel, T.J., Tregs and rethinking cancer immunotherapy (2007) Journal of Clinical Investigation, 117 (5), pp. 1167-1174. , http://www.jci.org/cgi/reprint/117/5/1167, DOI 10.1172/JCI31202Murray, P.J., Aldovini, A., Young, R.A., Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guérin strains that secrete cytokines (1996) Proc Natl Acad Sci USA, 93, pp. 934-939Cook, D.N., Pisetsky, D.S., Schwartz, D.A., Toll-like receptors in the pathogenesis of human disease (2004) Nat Immunol, 5, pp. 975-995Killeen, S.D., Wang, J.H., Andrews, E.J., Redmond, H.P., Exploitation of the toll-like receptor system in cancer: A doubled-edged sword? (2006) British Journal of Cancer, 95 (3), pp. 247-252. , DOI 10.1038/sj.bjc.6603275, PII 6603275Gearing, A.J.H., Targeting toll-like receptors for drug development: A summary of commercial approaches (2007) Immunology and Cell Biology, 85 (6), pp. 490-494. , DOI 10.1038/sj.icb.7100102, PII 7100102Erard, F., Ryffel, B., Toll like receptor - Potential drug targets in infectious disease (2008) Infect Disord Drug Targets, 8, pp. 221-231Hennessy, E.J., Parker, A.E., Oneill, L.A.J., Targeting Toll-like receptors: Emerging therapeutics? (2010) Nat Rev Drug Discov, 9, pp. 293-307Akira, S., Uematsu, S., Takeuchi, O., (2006) Pathogen Recognition and Innate Immunity. Cell, 124, pp. 783-801Srikrishna, G., Freeze, H.H., Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer (2009) Neoplasia, 11, pp. 615-628Huang, B., Zhao, J., Li, H., He, K.-L., Chen, Y., Mayer, L., Unkeless, J.C., Xiong, H., Toll-like receptors on tumor cells facilitate evasion of immune surveillance (2005) Cancer Research, 65 (12), pp. 5009-5014. , DOI 10.1158/0008-5472.CAN-05-0784Kelly, M.G., Alvero, A.B., Chen, R., Silasi, D.A., Abrahams, V.M., Chan, S., Visintin, I., Mor, G., TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer (2006) Cancer Res, 66, pp. 3859-3868Paone, A., Starace, D., Galli, R., Padula, F., De Cesaris, P., Filippini, A., Ziparo, E., Riccioli, A., Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC - Dependent mechanism (2008) Carcinogenesis, 29, pp. 1334-1342Simons, M.P., O'Donnell, M.A., Griffith, T.S., Role of neutrophils in BCG immunotherapy for bladder cancer (2008) Urologic Oncology: Seminars and Original Investigations, 26 (4), pp. 341-345. , DOI 10.1016/j.urolonc.2007.11.031, PII S1078143907002980Kowalski, M., Entwistle, J., Cizeau, J., Niforos, D., Loewen, S., Chapman, W., MacDonald, G.C., A Phase i study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients (2010) Drug des Devel Ther, 4, pp. 313-320Shelley, M.D., Court, J.B., Kynaston, H., Wilt, T.J., Fish, R.G., Mason, M., (2000) Intravesical Bacillus Calmette-Guerin in Ta and T1 Bladder Cancer, p. 4Zlotta, A.R., Van Vooren, J.-P., Denis, O., Drowart, A., Daffe, M., Lefevre, P., Schandene, L., Huygen, K., What are the immunologically active components of bacille calmette-guerin in therapy of superficial bladder cancer? (2000) International Journal of Cancer, 87 (6), pp. 844-852. , DOI 10.1002/1097-0215(20000915)87:63.0.CO;2-5Perabo, F.G.E., Willert, P.L., Wirger, A., Schmidt, D.H., Von Ruecker, A., Mueller, S.C., Superantigen-activated mononuclear cells induce apoptosis in transitional cell carcinoma (2005) Anticancer Research, 25 (5), pp. 3565-3573Heldwein, K.A., Liang, M.D., Andresen, T.K., Thomas, K.E., Marty, A.M., Cuesta, N., Vogel, S.N., Fenton, M.J., TLR2 and TLR4 serve distinct roles in the host immune response against Mycobacterium bovis BCG (2003) J Leukoc Biol, 74, pp. 277-2786Tsuji, S., Matsumoto, M., Takeuchi, O., Akira, S., Azuma, I., Hayashi, A., Toyoshima, K., Seya, T., Maturation of human dendritic cells by cell wall skeleton of Mycobacterium boris bacillus Calmette-Guérin: Involvement of toll-like receptors (2000) Infection and Immunity, 68 (12), pp. 6883-6890. , DOI 10.1128/IAI.68.12.6883-6890.2000Uehori, J., Matsumoto, M., Tsuji, S., Akazawa, T., Takeuchi, O., Akira, S., Kawata, T., Seya, T., Simultaneous blocking of human toll-like receptors 2 and 4 suppresses myeloid dendritic cell activation induced by Mycobacterium bovis bacillus Calmette-Guérin peptidoglycan (2003) Infection and Immunity, 71 (8), pp. 4238-4249. , DOI 10.1128/IAI.71.8.4238-4249.2003Oosterlinck, W., Lobel, B., Jackse, G., Malmström, P.U., Stöckle, M., Strenberg, C., European Association of Urology Recommendations 2001 Guidelines on bladder cancer (2002) Prog Urol, 12, pp. 1161-1163Tolley, D.A., Parmar, M.K.B., Grigor, K.M., Lallemand, G., Beynon, L.L., Fellows, S.J., Freedman, L.S., Whelan, P., The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: A further report with 7 years of followup (1996) Journal of Urology, 155 (4), pp. 1233-1238. , DOI 10.1016/S0022-5347(01)66226-8Durán, N., Gowen, B.B., Costa, F.T., Justo, G.Z., Brocchi, M., Nunes, O.S., Nunes, I.S., A biotechnological product and its potential as a new immunomodulator for treatment of animal phlebovirus infection: Punta Toro virus (2009) Antiviral Res, 83, pp. 143-147Reis, L.O., Fávaro, W.J., Ferreira, U., Billis, A., Fazuoli, M.G., Cagnon, V.H., Evolution on experimental animal model for upper urothelium carcinogenesis (2010) World J Urol, 28, pp. 499-505Reis, L.O., Ferreira, U., Billis, A., Castello, A.Z., Nunes, I.S., Durán, N., Cagnon, V.H., Fávaro, W.J., Putative Cancer Stem Cells (CSCS) signaling after immunotherapy with Bacillus Calmette-Guerin (BCG) and P-MAPA in the Superficial Bladder Cancer (SBC) [abstract] (2011) J Urol, 185, pp. 5200-e201Nunes, I., (2008) Building A New Model for PharmaceuticalsP-MAPA, A Novel Immunomodulator Against Virus, Bacterial, and Protozoan Infections, , www.ics.trieste.it/portal/ActivityDocument.aspx?id=5711, Abstract I-8. International Centre for Science and High Technology (ICS), United Nations Industrial Development Organization (UNIDO), United Nations Industrial Development Organization Accessed atP-MAPA Immunomodulator, , http://www.farmabrasilis.org.br/todos_conteudos_interna.php?idioma= eng&id=110Bromberg, N., Justo, G.J., Seabra, A.B., Durán, N., Macrophage nitric oxide (NO) stimulation by an immunomodulator: P-MAPA (2006) Nitric Oxide-Biol Chem, 14, p. 137(2009) The Farmabrasilis Infectious Diseases Proposal -3rd Stop TB Partners Forum -Rio 2009, , http://www.farmabrasilis.org.br/pesquisa_desenvolvimento_interna.php? idioma=eng&id=255Michelsen, K.S., Aicher, A., Mohaupt, M., Hartung, T., Dimmeler, S., Kirschning, C.J., Schumann, R.R., The role of toll-like receptors (TLRs) in bacteria-induced maturation of murine dendritic cells (DCS). Peptidoglycan and lipoteichoic acid are inducers of DC maturation and require TLR2 (2001) J Biol Chem, 276, pp. 25680-25686Thoma-Uszynski, S., Kiertscher, S.M., Ochoa, M.T., Bouis, D.A., Norgard, M.V., Miyake, K., Godowski, P.J., Modlin, R.L., Activation of Toll-like receptor 2 on human dendritic cells triggers induction of IL-12, but not IL-10 (2000) Journal of Immunology, 165 (7), pp. 3804-3810Abel, B., Thieblemont, N., Quesniaux, V.J.F., Brown, N., Mpagi, J., Miyake, K., Bihl, F., Ryffel, B., Toll-like receptor 4 expression is required to control chronic Mycobacterium tuberculosis infection in mice (2002) Journal of Immunology, 169 (6), pp. 3155-3162Barton, G.M., Medzhitov, R., Toll-like receptor signaling pathways (2003) Science, 300 (5625), pp. 1524-1525. , DOI 10.1126/science.1085536Brennan, P.J., Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis (2003) Tuberculosis, 83 (1-3), pp. 91-97. , DOI 10.1016/S1472-9792(02)00089-6Janeway, C.A., Medzhitov R: Innate immune recognition (2002) Annu Rev Immunol, 20, pp. 197-216Heine, H., Ulmer, A.J., Recognition of bacterial products by toll-like receptors (2005) Chemical Immunology and Allergy, 86, pp. 99-119Seya, T., Matsumoto, M., Tsuji, S., Begum, N.A., Nomura, M., Azuma, I., Hayashi, A., Toyoshima, K., Two receptor theory in innate immune activation: Studies on the receptors for bacillus culmet guillen-cell wall skeleton (2001) Arch Immunol Ther Exp (Warsz), 49 (SUPPL. 1), pp. 1913-S21Fricke, I., Mitchell, D., Mittelstädt, J., Lehan, N., Heine, H., Goldmann, T., Böhle, A., Brandau, S., Mycobacteria induce IFN-gamma production in human dendritic cells via triggering of TLR2 (2006) J Immunol, 176, pp. 5173-5182Ma, X., Liu, Y., Gowen, B.B., Graviss, E.A., Clark, A.G., Musser, J.M., Full-exon resequencing reveals toll-like receptor variants contribute to human susceptibility to tuberculosis disease (2007) PLoS One, 2, p. 51318Reiling, N., Hölscher, C., Fehrenbach, A., Kröger, S., Kirschning, C.J., Goyert, S., Ehlers, S., Cutting edge: Toll-like receptor (TLR)2- and TLR4-mediated pathogen recognition in resistance to airborne infection with Mycobacterium tuberculosis (2002) J Immunol, 169, pp. 3480-3484Branger, J., Leemans, J.C., Florquin, S., Weijer, S., Speelman, P., Van Der Poll, T., Toll-like receptor 4 plays a protective role in pulmonary tuberculosis in mice (2004) International Immunology, 16 (3), pp. 509-516. , DOI 10.1093/intimm/dxh052Flynn, J.L., Chan, J., Immunology of tuberculosis (2001) Annual Review of Immunology, 19, pp. 93-129. , DOI 10.1146/annurev.immunol.19.1.93Bulut, Y., Michelsen, K.S., Hayrapetian, L., Naiki, Y., Spallek, R., Singh, M., Arditi, M., Mycobacterium tuberculosis heat shock proteins use diverse toll-like receptor pathways to activate pro-inflammatory signals (2005) Journal of Biological Chemistry, 280 (22), pp. 20961-20967. , DOI 10.1074/jbc.M411379200Ayari, C., Bergeron, A., Larue, H., Ménard, C., Fradet, Y., Toll-like receptors in normal and malignant human bladders (2011) J Urol, 185, pp. 1915-1921Matijevic, T., Pavelic, J., Toll-like receptors: Cost or benefit for cancer? (2010) Curr Pharm des, 16, pp. 1081-1090Galli, R., Starace, D., Bus, R., Angelini, D.F., Paone, A., De Cesaris, P., Filippini, A., Riccioli, A., TLR stimulation of prostate tumor cells induces chemokine-mediated recruitment of specific immune cell types (2010) J Immunol, 184, pp. 6658-6669Huang, B., Zhao, J., Shen, S., Li, H., He, K.-L., Shen, G.-X., Mayer, L., Feng, Z.-H., Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling (2007) Cancer Research, 67 (9), pp. 4346-4352. , DOI 10.1158/0008-5472.CAN-06-4067Salaun, B., Lebecque, S., Matikainen, S., Rimoldi, D., Romero, P., Toll-like receptor 3 expressed by melanoma cells as a target for therapy? (2007) Clinical Cancer Research, 13 (15), pp. 4565-4574. , http://clincancerres.aacrjournals.org/cgi/reprint/13/15/4565, DOI 10.1158/1078-0432.CCR-07-0274Salaun, B., Coste, I., Rissoan, M.C., Lebecque, S.J., Renno, T., TLR3 can directly trigger apoptosis in human cancer cells (2006) J Immunol, 176, pp. 4894-4901Khvalevsky, E., Rivkin, L., Rachmilewitz, J., Galun, E., Giladi, H., TLR3 signaling in a hepatoma cell line is skewed towards apoptosis (2007) Journal of Cellular Biochemistry, 100 (5), pp. 1301-1312. , DOI 10.1002/jcb.21119He, W., Liu, Q., Wang, L., Chen, W., Li, N., Cao, X., TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance (2007) Molecular Immunology, 44 (11), pp. 2850-2859. , DOI 10.1016/j.molimm.2007.01.022, PII S0161589007000521Xie, W., Wang, Y., Huang, Y., Yang, H., Wang, J., Hu, Z., Toll-like receptor 2 mediates invasion via activating NF-kappaB in MDA-MB-231 breast cancer cells (2009) Biochem Biophys Res Commun, 379, pp. 1027-1032Goto, Y., Arigami, T., Kitago, M., Nguyen, S.L., Narita, N., Ferrone, S., Morton, D.L., Hoon, D.S., Activation of toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors (2008) Mol Cancer Ther, 7, pp. 3642-3653Zhou, M., McFarland-Mancini, M.M., Funk, H.M., Husseinzadeh, N., Mounajjed, T., Drew, A.F., Toll-like receptor expression in normal ovary and ovarian tumors (2009) Cancer Immunol Immunother, 58, pp. 1375-1385Matijevic, T., Marjanovic, M., Pavelic, J., Functionally active toll-like receptor 3 on human primary and metastatic cancer cells (2009) Scand J Immunol, 70, pp. 18-24Matijevic, T., Pavelic, J., The dual role of TLR3 in metastatic cell line (2011) Clin Exp Metastasis, 28, pp. 701-712Rakoff-Nahoum, S., Medzhitov, R., Toll-like receptors and cancer (2009) Nat Rev Cancer, 9, pp. 57-63Krieg, A.M., Development of TLR9 agonists for cancer therapy (2007) Journal of Clinical Investigation, 117 (5), pp. 1184-1194. , http://www.jci.org/cgi/reprint/117/5/1184, DOI 10.1172/JCI31414Mantovani, A., Allavena, P., Sica, A., Balkwill, F., (2008) Cancer-related Inflammation. Nature, 454, pp. 436-444Ben-Baruch, A., The multifaceted roles of chemokines in malignancy (2006) Cancer and Metastasis Reviews, 25 (3), pp. 357-371. , DOI 10.1007/s10555-006-9003-5, Special Issue on Pro-inflammatory Cytokines in CancerAllavena, P., Sica, A., Garlanda, C., Mantovani, A., The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance (2008) Immunological Reviews, 222 (1), pp. 155-161. , DOI 10.1111/j.1600-065X.2008.00607.xMalmberg, K.J., Bryceson, Y.T., Carlsten, M., Andersson, S., Björklund, A., Baumann, B.C., Fauriat, C., Ljunggren, H.G., NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy (2008) Cancer Immunol. Immunother, 57, pp. 1541-1552Proctor, M.J., Talwar, D., Balmar, S.M., O'Reilly, D.S., Foulis, A.K., Horgan, P.G., Morrison, D.S., McMillan, D.C., The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study (2010) Br J Cancer, 103, pp. 870-876Steinberg, G.D., Brendler, C.B., Ichikawa, T., Squire, R.A., Isaacs, J.T., Characterization of an N-methyl-N-nitrosourea induced autochthonous rat bladder cancer model (1990) Cancer Res, 50, pp. 6668-6741Reis, L.O., Pereira, T.C., Fávaro, W.J., Cagnon, V.H.A., Lopes-Cendes, I., Ferreira, U., Experimental animal model and RNA interference: A promising association for bladder cancer research (2009) World J Urol, 27, pp. 353-361Gunther, J.H., Jurczok, A., Wulf, T., Brandau, S., Deinert, I., Jocham, D., Bohle, A., Optimizing syngeneic orthotopic murine bladder cancer (MB49) (1999) Cancer Research, 59 (12), pp. 2834-2837Steinberg, G.D., Brendler, C.B., Squire, R.A., Isaacs, J.T., Experimental intravesical therapy for superWcial transitional cell carcinoma in a rat bladder tumor model (1991) J Urol, 145, pp. 647-653Odonnell, M.A., Practical applications of intravesical chemotherapy and immunotherapy in high-risk patients with superficial bladder cancer (2005) Urol Clin North Am, 32, pp. 121-131DiPaola, R.S., Lattime, E.C., Bacillus Calmette-Guerin Mechanism of Action: The Role of Immunity, Apoptosis, Necrosis and Autophagy (2007) Journal of Urology, 178 (5), pp. 1840-1841. , DOI 10.1016/j.juro.2007.08.063, PII S0022534707020708Bohle, A., Brandau, S., Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer (2003) Journal of Urology, 170 (3), pp. 964-969. , DOI 10.1097/01.ju.0000073852.24341.4aLudwig, A.T., Moore, J.M., Luo, Y., Chen, X., Saltsgaver, N.A., O'Donnell, M.A., Griffith, T.S., Tumor necrosis factor-related apoptosis-inducing ligand: A novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity (2004) Cancer Res, 64, pp. 338-3390Pavlovich, C.P., Kraling, B.M., Stewart, R.J., Chen, X., Bochner, B.H., Luster, A.D., Poppas, D.P., O'Donnell, M.A., BCG-induced urinary cytokines inhibit microvascular endothelial cell proliferation (2000) Journal of Urology, 163 (6), pp. 2014-2021Seow, S.W., Rahmat, J.N., Mohamed, A.A., Mahendran, R., Lee, Y.K., Bay, B.H., Lactobacillus species is more cytotoxic to human bladder cancer cells than Mycobacterium bovis (bacillus Calmette-Guerin) (2002) J Urol, 168, pp. 2236-2239Berry, D.L., Blumenstein, B.A., Magyarym, D.L., Lamm, D.L., Crawford, E.D., Local toxicity patterns associated with intravesical bacillus Calmette-Guérin: A Southwest Oncology Group study (1995) Int J Urol, 3, pp. 98-101Spruck, C.H., Ohnesiet PF, Gonzalez-Zulueta M: Two molecular pathways to transitional cell carcinoma of the bladder (1994) Cancer Res, 54, pp. 784-788Levine, A.J., P53, the cellular gatekeeper for growth and division (1997) Cell, 88 (3), pp. 323-331. , DOI 10.1016/S0092-8674(00)81871-1Erill, N., Colomer, A., Verdu, M., Roman, R., Condom, E., Hannaoui, N., Banus, J.M., Puig, X., Genetic and immunophenotype analyses of TP53 in bladder cancer: TP53 alterations are associated with tumor progression (2004) Diagnostic Molecular Pathology, 13 (4), pp. 217-223. , DOI 10.1097/01.pdm.0000137098.03878.00Sarkis, A.S., Dalbagni, G., Cordon-Cardo, C., Zhang, Z.-F., Sheinfeld, J., Fair, W.R., Herr, H.W., Reuter, V.E., Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: A marker for disease progression (1993) Journal of the National Cancer Institute, 85 (1), pp. 53-59Ahrendt, S.A., Hu, Y., Buta, M., McDermott, M.P., Benoit, N., Yang, S.C., Wu, L., Sidransky, D., P53 mutations and survival in stage I non-small-cell lung cancer: Results of a prospective study (2003) Journal of the National Cancer Institute, 95 (13), pp. 961-970Wen, W.H., Press, M.F., Identification of TP53 mutations in human cancers using oligonucleotide microarrays (2004) Methods Mol Med, 97, pp. 323-335Olivier, M., Langerod, A., Carrieri, P., Bergh, J., Klaar, S., Eyfjord, J., Theillet, C., Borresen-Dale, A.-L., The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer (2006) Clinical Cancer Research, 12 (4), pp. 1157-1167. , DOI 10.1158/1078-0432.CCR-05-1029Menendez, D., Shatz, M., Azzam, K., Garantziotis, S., Fessler, M.B., Resnick, M.A., The Toll-like receptor gene family is integrated into human DNA damage and p53 networks (2011) PLoS Genet, 7, p. 51001360Collins, L.A., Franzblau, S.G., Microplate Alamar blue assay versus BACTEC 460 system for high- throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium (1997) Antimicrobial Agents and Chemotherapy, 41 (5), pp. 1004-1009North, R.J., Izzo, A.A., Mycobacterial virulence. Virulent strains of Mycobacteria tuberculosis have faster in vivo doubling times and are better equipped to resist growth- inhibiting functions of macrophages in the presence and absence of specific immunity (1993) Journal of Experimental Medicine, 177 (6), pp. 1723-1733Lenaerts, A.J., Gruppo, V., Marietta, K.S., Johnson, C.M., Driscoll, D.K., Tompkins, N.M., Rose, J.D., Orme, I.M., Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models (2005) Antimicrobial Agents and Chemotherapy, 49 (6), pp. 2294-2301. , DOI 10.1128/AAC.49.6.2294-2301.2005Kelly, B.P., Furney, S.K., Jessen, M.T., Orme, I.M., Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis (1996) Antimicrobial Agents and Chemot

Melatonin And Ethanol Intake Exert Opposite Effects On Circulating Estradiol And Progesterone And Differentially Regulate Sex Steroid Receptors In The Ovaries, Oviducts, And Uteri Of Adult Rats

Chronic ethanol intake is associated with sex hormone disturbances, and it is well known that melatonin plays a key role in regulating several reproductive processes. We report the effects of ethanol intake and melatonin treatment (at doses of 100. μg/100. g. BW/day) on sex hormones and steroid receptors in the ovaries, oviducts and uteri of ethanol-preferring rats. After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, progesterone and melatonin receptor subunits (AR, ER-α and ER-β, PRA, PRB and MT1R, respectively). Melatonin decreased estradiol (E2) and increased progesterone (P4) and 6-sulfatoxymelatonin (6-STM), while an ethanol-melatonin combination reduced both P4 and E2. Ovarian AR was not influenced by either treatment, and oviduct AR was reduced after ethanol-melatonin combination. Oviduct ER-α, ER-β and uterine ER-β were down-regulated by either ethanol or melatonin. Conversely, ovarian PRA and PRB were positively regulated by ethanol and ethanol-melatonin combination, whereas PRA was down-regulated in the uterus and oviduct after ethanol consumption. MT1R was increased in ovaries and uteri of melatonin-treated rats. Ethanol and melatonin exert opposite effects on E2 and P4, and they differentially regulate the expression of sex steroid receptors in female reproductive tissues. © 2013 Elsevier Inc.394049Carrara, O., Oger-Jeannin, V., Desechalliers, J.P., Disorders of the hypothalamo-hypophyseal-ovarian axis in chronic alcoholic women (1993) La Revue de Médecine Interne, 14, pp. 9-13Henderson, J., Gray, R., Brocklehurst, P., Systematic review of effects of low-moderate prenatal alcohol exposure on pregnancy outcome (2007) BJOG, 114, pp. 243-252Chuffa, L.G., Amorim, J.P., Teixeira, G.R., Mendes, L.O., Fioruci, B.A., Pinheiro, P.F., Long-term exogenous melatonin treatment modulates overall feed efficiency and protects ovarian tissue against injuries caused by ethanol-induced oxidative stress in adult UChB rats (2011) Alcoholism: Clinical and Experimental Research, 35, pp. 1498-1508Chuffa, L.G., Padovani, C.R., Martinez, F.E., Ovarian structure and hormonal status of the UChA and UChB adult rats in response to ethanol (2009) Maturitas, 62, pp. 21-29Dees, W.L., Srivastava, V.K., Hiney, J.K., Alcohol alters insulin-like growth factor-1 activated Oct-2 POU gene expression in the immature female hypothalamus (2005) Journal of Studies on Alcohol, 66, pp. 35-45Hiney, J.K., Dearth, R.K., Srivastava, V.K., Rettori, V., Dees, W.L., Actions of ethanol on epidermal growth factor receptor activated luteinizing hormone secretion (2003) Journal of Studies on Alcohol, 64, pp. 809-816Emanuele, N.V., LaPaglia, N., Steiner, J., Kirsteins, L., Emanuele, M.A., Effect of chronic ethanol exposure on female rat reproductive cyclicity and hormone secretion (2001) Alcoholism: Clinical and Experimental Research, 25, pp. 1025-1029Alfonso, M., Durán, R., Marcó, J., Ethanol-induced alterations in gonadotrophins secretion during the estrous cycle of rats (1993) Alcohol and Alcoholism, 28, pp. 667-674Mardones, J., Segovia-Riquelme, N., Thirty-two years of selection of rats by ethanol preference: UChA and UChB strains (1983) Neurobehavioral Toxicology and Teratology, 5, pp. 171-178Masana, M.I., Dubocovich, M.L., Melatonin receptor signaling: finding the path through the dark (2001) Science's STKE, 107, pp. pe39Peres, R., do Amaral, F.G., Madrigrano, T.C., Ethanol consumption and pineal melatonin daily profile in rats (2011) Addiction Biology, 16, pp. 580-590Malpaux, B., Migaud, M., Tricoire, H., Chemineau, P., Biology of mammalian photoperiodism and the critical role of the pineal gland and melatonin (2001) Journal of Biological Rhythms, 16, pp. 336-347Reiter, R.J., Johnson, L.Y., Vanghan, M.K., Richardson, B.A., Petterborg, L.J., Variation in pineal melatonin content during the estrous cycle of the rat (1982) Proceedings of the Society for Experimental Biology and Medicine, 169, pp. 416-419Tamura, H., Nakamura, Y., Takiguchi, S., Kashida, S., Yamagata, T., Sugino, N., Melatonin directly suppresses steroid production by preovulatory follicles in the cyclic hamster (1998) Journal of Pineal Research, 25, pp. 135-141Nakamura, Y., Tamura, H., Takayama, H., Kato, H., Increased endogenous level of melatonin in preovulatory human follicles does not directly influence progesterone production (2003) Fertility and Sterility, 80, pp. 1012-1016Kuiper, G.G., Enmark, E., Pelto Huikko, M., Nilsson, S., Gustafsson, J.A., Cloning of a novel estrogen receptor expressed in rat prostate and ovary (1996) Proceedings of the National Academy of Sciences of the United States of America, 93, pp. 5925-5930Okada, A., Sato, T., Ohta, Y., Iguchi, T., Sex steroid hormone receptors in the developing female reproductive tract of laboratory rodents (2005) Journal of Toxicological Sciences, 30, pp. 75-89Chuffa, L.G., Seiva, F.R., Favaro, W.J., Teixeira, G.R., Amorim, J.P., Mendes, L.O., Melatonin reduces LH, 17 beta-estradiol and induces differential regulation of sex steroid receptors in reproductive tissues during rat ovulation (2011) Reproductive Biology and Endocrinology, 9, p. 108Romeu, L.R., da Motta, E.L., Maganhin, C.C., Oshima, C.T., Fonseca, M.C., Barrueco, K.F., Effects of melatonin on histomorphology and on the expression of steroid receptors, VEGF, and PCNA in ovaries of pinealectomized female rats (2011) Fertility and Sterility, 95, pp. 1379-1384Wang, G., Chen, D., Luo, H., Liu, J., Ji, X., Fan, J., Low-dose ethanol suppresses 17β-estradiol activity in GH4C1 pituitary tumor cells (2010) Cell Biology and Toxicology, 26, pp. 265-277Kraus, W.L., Montano, M.M., Katzenellenbogen, B.S., Identification of multiple, widely spaced estrogen-responsive regions in the rat progesterone receptor gene (1994) Molecular Endocrinology, 8, pp. 952-969Mulac-Jericevic, B., Lydon, J.P., DeMayo, F.J., Conneely, O.M., Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform (2003) Proceedings of the National Academy of Sciences of the United States of America, 100, pp. 9744-9749Horne, A.W., King, A.E., Shaw, E., McDonald, S.E., Williams, A.R., Saunders, P.T., Attenuated sex steroid receptor expression in fallopian tube of women with ectopic pregnancy (2009) Journal of Clinical Endocrinology & Metabolism, 94, pp. 5146-5154Ma, H., Bernstein, L., Ross, R.K., Ursin, G., Hormone-related risk factors for breast cancer in women under age 50 years by estrogen and progesterone receptor status: results from a case-control and a case-case comparison (2006) Breast Cancer Research, 8, pp. R39Benitez-King, G., Melatonin as a cytoskeletal modulator: implications for cell physiology and disease (2006) Journal of Pineal Research, 40, pp. 1-9Molis, T.M., Spriggs, L.L., Hill, S.M., Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells (1994) Molecular Endocrinology, 8, pp. 1681-1690Rato, A.G., Pedrero, J.G., Martinez, M.A., del Rio, B., Lazo, O.S., Ramos, S., Melatonin blocks the activation of estrogen receptor for DNA binding (1999) FASEB Journal, 13, pp. 857-868de Almeida Chuffa, L.G., de Souza, R.B., Frei, F., de Fátima Paccola Mesquita, S., Camargo, I.C., Nandrolone decanoate and physical effort: histological and morphometrical assessment in adult rat uterus (2011) Anatomical Record, 294, pp. 335-341Chuffa, L.G., Amorim, J.P., Teixeira, G.R., Mendes, L.O., Fioruci, B.A., Pinheiro, P.F., Long-term melatonin treatment reduces ovarian mass and enhances tissue antioxidant defenses during ovulation in the rat (2011) Brazilian Journal of Medical and Biological Research, 44, pp. 217-223Bradford, M.M., A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding (1976) Analytical Biochemistry, 72, pp. 248-254Laemmli, U.K., Cleavage of structural proteins during the assembly of the head of bacteriophage T4 (1970) Nature, 227, pp. 680-685Malpaux, B., Thiéry, J.C., Chemineau, P., Melatonin and the seasonal control of reproduction (1999) Reproduction Nutrition Development, 39, pp. 355-366Srivastava, V.K., Hiney, J.K., Les Dees, W., Short-term alcohol administration alters Kiss-1 gene expression in the reproductive hypothalamus of prepubertal female rats (2009) Alcoholism: Clinical and Experimental Research, 33, pp. 1605-1614Revel, F.G., Ansel, L., Klosen, P., Saboureau, M., Pévet, P., Mikkelsen, J.D., Kisspeptin: a key link to seasonal breeding (2007) Reviews in Endocrine & Metabolic Disorders, 8, pp. 57-65Crespi, F., Influence of melatonin or its antagonism on alcohol consumption in ethanol drinking rats: a behavioral and in vivo voltammetric study (2012) Brain Research, 1452, pp. 39-46Martínez-Campa, C., González, A., Mediavilla, M.D., Alonso-González, C., Sánchez-Barceló, E.J., Cos, S., Melatonin enhances the inhibitory effect of aminoglutethimide on aromatase activity in MCF-7 human breast cancer cells (2005) Breast Cancer Research and Treatment, 94, pp. 249-254Verkasalo, P.K., Thomas, H.V., Appleby, P.N., Davey, G.K., Key, T.J., Circulating levels of sex hormones and their relation to risk factor for breast cancer: a cross-sectional study in 1092 pre-and postmenopausal women (United Kingdom) (2001) Cancer Causes and Control, 12, pp. 47-59Macchi, M.M., Bruce, J.N., Human pineal physiology and functional significance of melatonin (2004) Frontiers in Neuroendocrinology, 25, pp. 177-195Anderson, S., Moghrabi, N., Physiology and molecular genetics of 17P-hydroxysteroid dehydrogenases (1997) Steroids, 62, pp. 143-147Aronika, S.M., Kraus, W.L., Katzenellenbogen, B.S., Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription (1994) Proceedings of the National Academy of Sciences of the United States of America, 91, pp. 8517-8521Godson, C., Reppert, S.M., The mel1a melatonin receptor is coupled to parallel signal transduction pathways (1997) Endocrinology, 138, pp. 397-404Singletary, K.W., Frey, R.S., Yan, W., Effect of ethanol on proliferation and estrogen receptor-alpha expression in human breast cancer cells (2001) Cancer Letters, 165, pp. 131-137Fan, S., Meng, Q., Gao, B., Grossman, J., Yadegari, M., Goldberg, I.D., Alcohol stimulates estrogen receptor signaling in human breast cancer cell lines (2000) Cancer Research, 60, pp. 5635-5639Chalbos, D., Galtier, F., Differential effect of forms A and B of human progesterone receptor on estradiol-dependent transcription (1994) Journal of Biological Chemistry, 269, pp. 23007-23012Okatani, Y., Watanabe, K., Morioka, N., Hayashi, K., Sagara, Y., Nocturnal change in pineal melatonin synthesis during puberty: relation to estrogen and progesterone levels in female rats (1997) Journal of Pineal Research, 22, pp. 33-41Purohit, V., Can alcohol promote aromatization of androgens to estrogens? A review (2000) Alcohol, 22, pp. 123-127Panet-Raymond, V., Gottlieb, B., Beitel, L.K., Pinsky, L., Trifiro, M.A., Interactions between androgen and estrogen receptors and the effects on their transactivational properties (2000) Molecular and Cellular Endocrinology, 167, pp. 139-150Chen, J.R., Lazarenko, O.P., Haley, R.L., Blackburn, M.L., Badger, T.M., Ronis, M.J., Ethanol impairs estrogen receptor signaling resulting in accelerated activation of senescence pathways while estradiol attenuates the effects of ethanol in osteoblasts (2009) Journal of Bone and Mineral Research, 24, pp. 221-230Eriksson, C.J., Fugunaga, T., Lindman, R., Sex hormone response to alcohol (1994) Nature, 369, p. 711Sarkola, T., Fukunaga, T., Makisalo, H., Peter Eriksson, C.J., Acute effect of alcohol on androgens in premenopausal women (2000) Alcohol and Alcoholism, 35, pp. 84-90Li, W., Boomsma, R.A., Verhage, H.G., Immunocytochemical analysis of estrogen and progestin receptors in uteri of steroid-treated and pregnant cats (1992) Biology of Reproduction, 47, pp. 1073-1081Zhao, H., Pang, S.F., Poon, A.M., Variations of mt1 melatonin receptor density in the rat uterus during decidualization, the estrous cycle and in response to exogenous steroid treatment (2002) Journal of Pineal Research, 33, pp. 140-145Tibbetts, T.A., Mendoza-Meneses, M., O'Malley, B.W., Conneely, O.M., Mutual and intercompartmental regulation of estrogen receptor and progesterone receptor expression in the mouse uterus (1998) Biology of Reproduction, 59, pp. 1143-1152Abd-Allah, A.R., El-Sayed, E.M., Abdel-Wahab, M.H., Hamada, F.M., Effect of melatonin on estrogen and progesterone receptors in relation to uterine contraction in rats (2003) Pharmacological Research, 47, pp. 349-354Cloke, B., Huhtinen, K., Fusi, L., Kajihara, T., Yliheikkilä, M., Ho, K.K., The androgen and progesterone receptors regulate distinct gene networks and cellular functions in decidualizing endometrium (2008) Endocrinology, 149, pp. 4462-4474Arnett-Mansfield, R.L., deFazio, A., Wain, G.V., Jaworski, R.C., Byth, K., Mote, P.A., Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium (2001) Cancer Research, 61, pp. 4576-4582De Vivo, I., Huggins, G.S., Hankinson, S.E., Lescault, P.J., Boezen, M., Colditz, G.A., A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk (2002) Proceedings of the National Academy of Sciences of the United States of America, 99, pp. 12263-1226

Long-term melatonin treatment reduces ovarian mass and enhances tissue antioxidant defenses during ovulation in the rat

Melatonin regulates the reproductive cycle, energy metabolism and may also act as a potential antioxidant indoleamine. The present study was undertaken to investigate whether long-term melatonin treatment can induce reproductive alterations and if it can protect ovarian tissue against lipid peroxidation during ovulation. Twenty-four adult female Wistar rats, 60 days old (± 250-260 g), were randomly divided into two equal groups. The control group received 0.3 mL 0.9% NaCl + 0.04 mL 95% ethanol as vehicle, and the melatonin-treated group received vehicle + melatonin (100 µg·100 g body weight-1·day-1) both intraperitoneally daily for 60 days. All animals were killed by decapitation during the morning estrus at 4:00 am. Body weight gain and body mass index were reduced by melatonin after 10 days of treatment (P < 0.05). Also, a marked loss of appetite was observed with a fall in food intake, energy intake (melatonin 51.41 ± 1.28 vs control 57.35 ± 1.34 kcal/day) and glucose levels (melatonin 80.3 ± 4.49 vs control 103.5 ± 5.47 mg/dL) towards the end of treatment. Melatonin itself and changes in energy balance promoted reductions in ovarian mass (20.2%) and estrous cycle remained extensive (26.7%), arresting at diestrus. Regarding the oxidative profile, lipid hydroperoxide levels decreased after melatonin treatment (6.9%) and total antioxidant substances were enhanced within the ovaries (23.9%). Additionally, melatonin increased superoxide dismutase (21.3%), catalase (23.6%) and glutathione-reductase (14.8%) activities and the reducing power (10.2% GSH/GSSG ratio). We suggest that melatonin alters ovarian mass and estrous cyclicity and protects the ovaries by increasing superoxide dismutase, catalase and glutathione-reductase activities